Posts tagged TRPV6
Soricimed planning to initiate Phase 1b/2a solid tumor trial in Q2

Closely-held Soricimed Biopharma expects to initiate in the second quarter of 2018 a Phase 1b/2a clinical trial with its SOR-C13 drug candidate in patients with prostate cancer, including men who have failed first line treatment, as well as patients with advanced pancreatic and ovarian cancers.

Read More
In conversation with Paul Gunn

As president and CEO of closely-held Soricimed Biopharma, Paul Gunn parlayed a 20-year career as a financial executive into funding the startup of Soricimed along with a tech transfer in 2005 facilitated by Mount Allison University in Sackville, New Brunswick, Canada. Admittedly, he was new to biotech and drug development in those days, but he moved into Soricimed as CFO in 2007 and became CEO a few years later. Today, the company is gaining an international following with its anti-cancer drug candidate, SOR-C13, and successful early human studies in solid cancer types. The company presented four posters at the American Association of Cancer Research in New Orleans last week about its preclinical and clinical research and supporting data. In this interview with, Mr. Gunn discusses the early success of SOR-C13 and the drug’s future potential.

Read More